NCI-2025-01103

A Phase II/III, multisite, randomized master protocol for a global trial of BNT327in combination with chemotherapy and other investigational agents in first-linenon-small cell lung cancer

This Phase II/III research study is a randomized, multisite master-protocol study evaluating BNT327, an investigational bispecific antibody in combination with standard chemotherapy and other investigational agents for patients with first-line advanced non-small cell lung cancer (NSCLC). BNT327 is designed to engage two targets simultaneously—PD-L1 (an immune checkpoint protein) and VEGF-A (a factor involved in tumor blood vessel formation). By blocking PD-L1, it encourages the immune system to attack tumor cells, and by inhibiting VEGF-A, it disrupts the tumor’s blood supply and immune-suppressive micro-environment. If successful, this trial could support BNT327 becoming a new first-line treatment option for NSCLC by targeting both immune-evading and angiogenic mechanisms that promote tumor growth.

Phase 2: An advanced point of testing, where they're trying to confirm if a treatment works well.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

Randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

Non Small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06712316

Clinical Trial Site: Einstein

To see all available clinical trials click here.